(Natalia Mittelstadt) The European Medicines Agency (EMA) listed Guillain-Barré syndrome as a “very rare” side effect of AstraZeneca’s COVID-19 vaccine on Wednesday.
An Agent for Consciousness Evolution
(Natalia Mittelstadt) The European Medicines Agency (EMA) listed Guillain-Barré syndrome as a “very rare” side effect of AstraZeneca’s COVID-19 vaccine on Wednesday.